STOCK TITAN

89Bio Stock Price, News & Analysis

ETNB NASDAQ

Company Description

Overview

89Bio, Inc. (symbol: ETNB) is a United States-based clinical-stage biopharmaceutical company committed to advancing innovative therapies for patients with liver and cardiometabolic diseases. Employing cutting-edge glycoPEGylation technology, the company is focused on enhancing the biological activity and prolonging the half-life of its therapeutic candidates through advanced drug engineering. With a robust pipeline centered on conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG), 89Bio is addressing significant unmet clinical needs with precision and scientific rigor.

Core Business and Product Pipeline

The company’s primary focus is on the development and eventual commercialization of pegozafermin, a specifically engineered fibroblast growth factor 21 (FGF21) analog. This molecule, enhanced by unique glycoPEGylated technology, has been designed to exert potent anti-fibrotic and metabolic effects. It aims to treat advanced liver conditions by reducing fibrosis and ameliorating metabolic dysregulation, a dual approach that positions 89Bio uniquely in the biotech landscape. Beyond its lead candidate, the company continues to explore additional therapeutic avenues within the liver and cardiometabolic realms, ensuring a diversified approach to clinical development.

Clinical Development and Research

89Bio has structured its clinical research around rigorous Phase 3 trials, notably the ENLIGHTEN program, which encompasses pivotal studies in both non-cirrhotic MASH (with fibrosis stages F2-F3) and MASH with compensated cirrhosis (F4). These randomized, double-blind, placebo-controlled trials are designed to evaluate key endpoints such as histological improvements in liver fibrosis and resolution of steatohepatitis. By integrating noninvasive diagnostic tools alongside traditional biopsy assessments, the company aims to streamline patient evaluation and enhance the sensitivity of therapeutic response measurement. Moreover, the advanced design of these trials reflects 89Bio's commitment to scientific excellence and clear regulatory communication, as evidenced by recent supportive designations from global regulatory bodies.

Stock Performance

$14.87
+0.01%
+0.00
Last updated: September 22, 2025 at 11:21
16.01 %
Performance 1 year
$2.2B

Financial Highlights

$0
Revenue (TTM)
-$149,073,000
Net Income (TTM)
-$145,359,000
Operating Cash Flow
-$151,938,000

Upcoming Events

October 1, 2025 - December 31, 2025
Acquisition closing
Expected closing of Roche acquisition of 89bio subject to regulatory approvals
January 1, 2026
ENTRUST trial topline data
January 1, 2026
ENTRUST trial topline data
January 1, 2026 - March 31, 2026
ENTRUST data readout
Topline Phase 3 ENTRUST trial data for severe hypertriglyceridemia
January 1, 2027 - June 30, 2027
ENLIGHTEN data readout
Phase 3 ENLIGHTEN trials data for MASH treatment
January 1, 2028 - June 30, 2028
ENLIGHTEN data readout
Phase 3 ENLIGHTEN trials data for MASH treatment

Short Interest History

Last 12 Months
Loading short interest data...

Days to Cover History

Last 12 Months
Loading days to cover data...

Frequently Asked Questions

What is the current stock price of 89Bio (ETNB)?

The current stock price of 89Bio (ETNB) is $14.87 as of September 19, 2025.

What is the market cap of 89Bio (ETNB)?

The market cap of 89Bio (ETNB) is approximately 2.2B. Learn more about what market capitalization means.

What is the revenue (TTM) of 89Bio (ETNB) stock?

The trailing twelve months (TTM) revenue of 89Bio (ETNB) is $0.

What is the net income of 89Bio (ETNB)?

The trailing twelve months (TTM) net income of 89Bio (ETNB) is -$149,073,000.

What is the earnings per share (EPS) of 89Bio (ETNB)?

The diluted earnings per share (EPS) of 89Bio (ETNB) is -$1.39 on a trailing twelve months (TTM) basis. Learn more about EPS.

What is the operating cash flow of 89Bio (ETNB)?

The operating cash flow of 89Bio (ETNB) is -$145,359,000. Learn about cash flow.

What is the current ratio of 89Bio (ETNB)?

The current ratio of 89Bio (ETNB) is 11.66, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.

What is the operating income of 89Bio (ETNB)?

The operating income of 89Bio (ETNB) is -$151,938,000. Learn about operating income.

What is 89Bio, Inc. known for?

89Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for liver and cardiometabolic diseases. Its scientific expertise is demonstrated through advanced therapeutic candidates such as pegozafermin, a glycoPEGylated analog of FGF21.

What therapeutic areas does 89Bio target?

The company targets liver diseases, specifically metabolic dysfunction-associated steatohepatitis (MASH), and cardiometabolic conditions such as severe hypertriglyceridemia. These areas represent significant unmet clinical needs, fueling 89Bio's strategic research and development efforts.

What is pegozafermin and why is it important?

Pegozafermin is 89Bio's lead product candidate, designed as a glycoPEGylated analog of FGF21. It is engineered to improve liver fibrosis and regulate metabolic parameters, offering a novel dual mechanism that is critical for treating complex conditions like MASH and SHTG.

How is 89Bio advancing its clinical programs?

89Bio is advancing its clinical programs through a series of rigorously designed Phase 3 trials, including the ENLIGHTEN program for MASH. These trials use robust methodologies, combining noninvasive diagnostic techniques with traditional histological assessments to evaluate therapeutic efficacy.

What differentiates the glycoPEGylated technology used by 89Bio?

The glycoPEGylated technology enhances the stability and prolongs the half-life of therapeutic molecules, such as pegozafermin. This technology optimizes biological activity, ensuring sustained efficacy while potentially improving safety and patient adherence through more convenient dosing schedules.

Where is 89Bio headquartered and what is its background?

89Bio is headquartered in San Francisco, California, and was founded in 2018. Since its inception, the company has been dedicated to addressing critical unmet needs in liver and cardiometabolic diseases through advanced therapeutic research and clinical innovation.